Serotype-specific neutralizing antibody epitopes of human adenovirus type 3 (HAdV-3) and HAdV-7 reside in multiple hexon hypervariable regions

Journal of Virology

Volumn 86, Issue 15, 2012, Pages 7964-7975

  Qiu, Hongling ^a,b   Li, Xiao ^a   Tian, Xingui ^a   Zhou, Zhichao ^a   Xing, Ke ^a   Li, Haitao ^a   Tang, Ni ^a   Liu, Wenkuan ^a   Bai, Peisheng ^a   Zhou, Rong ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b Chinese Academy of Sciences   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ADENOVIRUS VIRUS VACCINE; EPITOPE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS VACCINE;

ADENOVIRUS; ADENOVIRUS 3; ADENOVIRUS 7; ADENOVIRUS INFECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; FEMALE; HUMORAL IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; INFECTION RESISTANCE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEROTYPE;

ADENOVIRUS INFECTIONS, HUMAN; ADENOVIRUSES, HUMAN; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CAPSID PROTEINS; EPITOPES; FEMALE; GENE TRANSFER TECHNIQUES; MICE; MICE, INBRED BALB C; SPECIES SPECIFICITY; VIRAL VACCINES;

ADENOVIRIDAE; HUMAN ADENOVIRUS; HUMAN ADENOVIRUS TYPE 3;

EID: 84864394236     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.07076-11     Document Type: Article

References (32)

1. Bradley RR, et al. 2012. Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions. J. Virol. 86:1267-1272.
2. Choi EH, et al. 2005. Adenovirus type 7 peptide diversity during outbreak, Korea, 1995-2000. Emerg. Infect. Dis. 11:649-654.
3. Chuang YY, et al. 2003. Severe adenovirus infection in children. J. Microbiol. Immunol. Infect. 36:37-40.
4. Crawford-Miksza L, Schnurr DP. 1996. Analysis of 15 adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residues. J. Virol. 70:1836-1844.
5. Crawford-Miksza LK, Schnurr DP. 1994. Quantitative colorimetric microneutralization assay for characterization of adenoviruses. J. Clin. Microbiol. 32:2331-2334.
6. de Jong JC, Osterhaus AD, Jones MS, Harrach B. 2008. Human adenovirus type 52: a type 41 in disguise? J. Virol. 82:3809. (Letter.)
7. Ebner K, Pinsker W, Lion T. 2005. Comparative sequence analysis of the hexon gene in the entire spectrum of human adenovirus serotypes: phylogenetic, taxonomic, and clinical implications. J. Virol. 79:12635-12642.
8. Eswar N, Eramian D, Webb B, Shen MY, Sali A. 2008. Protein structure modeling with MODELLER. Methods Mol. Biol. 426:145-159.
9. Guo L, et al. 2012. Detection of three human adenovirus species in adults with acute respiratory infection in China. Eur. J. Clin. Microbiol. Infect. Dis. 31:1051-1058.
10. Hayashi S, Hogg JC. 2007. Adenovirus infections and lung disease. Curr. Opin. Pharmacol. 7:237-243.
11. James L, et al. 2007. Outbreak of human adenovirus type 3 infection in a pediatric long-term care facility-Illinois, 2005. Clin. Infect. Dis. 45:416-420.
12. Jones MS, II, et al. 2007. New adenovirus species found in a patient presenting with gastroenteritis. J. Virol. 81:5978-5984.
13. Knopf HL, Hierholzer JC. 1975. Clinical and immunologic responses in patients with viral keratoconjunctivitis. Am. J. Ophthalmol. 80:661-672.
14. Lee J, Choi EH, Lee HJ. 2010. Clinical severity of respiratory adenoviral infection by serotypes in Korean children over 17 consecutive years (1991-2007). J. Clin. Virol. 49:115-120.
15. Mitchell LS, Taylor B, Reimels W, Barrett FF, Devincenzo JP. 2000. Adenovirus 7a: a community-acquired outbreak in a children's hospital. Pediatr. Infect. Dis. J. 19:996-1000.
16. Reference deleted
17. Pichla-Gollon SL, et al. 2007. Structure-based identification of a major neutralizing site in an adenovirus hexon. J. Virol. 81:1680-1689.
18. Qiu H, et al. 2009. Epitope mapping and cross-reactivity analysis of the monoclonal antibodies against hexon protein of human adenovirus type Virus Res. 146:58-65.
19. Roberts DM, et al. 2006. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441:239-243.
20. Rux JJ, Burnett RM. 2000. Type-specific epitope locations revealed by X-ray crystallographic study of adenovirus type 5 hexon. Mol. Ther. 1:18-30.
21. Selvaraju SB, Kovac M, Dickson LM, Kajon AE, Selvarangan R. 2011. Molecular epidemiology and clinical presentation of human adenovirus infections in Kansas City children. J. Clin. Virol. 51:126-131.
22. Reference deleted
23. Sprangers MC, et al. 2003. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J. Clin. Microbiol. 41:5046-5052.
24. Sumida SM, et al. 2005. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J. Immunol. 174:7179-7185.
25. Sumida SM, et al. 2004. Neutralizing antibodies and CD8_ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J. Virol. 78:2666-2673.
26. Tang L, Wang L, Tan X, Xu W. 2011. Adenovirus serotype 7 associated with a severe lower respiratory tract disease outbreak in infants in Shaanxi Province, China. Virol. J. 8:23.
27. Tian X, et al. 2011. Construction and characterization of human adenovirus serotype 3 packaged by serotype 7 hexon. Virus Res. 160: 214-220.
28. Wang Z, Mo C, Kemble G, Duke G. 2004. Development of an efficient fluorescence-based microneutralization assay using recombinant human cytomegalovirus strains expressing green fluorescent protein. J. Virol. Methods 120:207-215.
29. Reference deleted
30. Yuan X, et al. 2009. Molecular modeling and epitopes mapping of human adenovirus type 3 hexon protein. Vaccine 27:5103-5110.
31. Zhang Q, et al. 2006. Comparative genomic analysis of two strains of human adenovirus type 3 isolated from children with acute respiratory infection in southern China. J. Gen. Virol. 87:1531-1541.
32. Zhang Q, et al. 2009. Construction and characterization of a replicationcompetent human adenovirus type 3-based vector as a live-vaccine candidate and a viral delivery vector. Vaccine 27:1145-1153.